12.75亿！合成生物制造，落地浙江富阳！

Core Viewpoint - The article highlights the launch of a significant industrial project by Bojiao Biotechnology, focusing on synthetic biology and green manufacturing, with a total investment of 1.275 billion yuan, aiming for production capacity and substantial annual sales revenue [1][3]. Group 1: Project Overview - Bojiao Biotechnology's industrialization and research project is a provincial key industrial initiative with a total investment of 1.275 billion yuan [1]. - The project is expected to complete its core production and supporting facilities from January 2026 to June 2027, with production capacity reaching 156.2 tons of raw materials, 300 million dosage forms, and 15 million bottles annually [1]. - The anticipated annual sales revenue is projected to exceed 5 billion yuan, with annual tax and profit exceeding 500 million yuan [1]. Group 2: Technological Focus - The project is centered around synthetic biology, integrating AI smart manufacturing and green manufacturing concepts, establishing a comprehensive technical system from strain construction to structural modification [1]. - Bojiao Biotechnology has developed four major technology platforms, including molecular biology, enzyme engineering, green chemistry, and drug delivery, positioning itself in the core technology of terpenoid pharmaceuticals [4]. - The company collaborates closely with Jay Keasling, a pioneer in synthetic biology, and his company Demetrix, aiming to develop more efficient and sustainable biosynthetic processes [5].